TUMOR-ACTIVATED FC-ENGINEERED ANTI-CTLA-4 MONOCLONAL ANTIBODY, XTX101, DEMONSTRATES TUMOR-SELECTIVE PD AND EFFICACY IN PRECLINICAL MODELS-MedSci.cn

TUMOR-ACTIVATED FC-ENGINEERED ANTI-CTLA-4 MONOCLONAL ANTIBODY, XTX101, DEMONSTRATES TUMOR-SELECTIVE PD AND EFFICACY IN PRECLINICAL MODELS

Jenkins, K; Johnson, P; Zhang, MJ; Guzman, W; Eskiocak, U; McLaughlin, M; O'Toole, C; Pederzoli-Ribeil, M; Park, M; Williams, J; Karow, M; O'Neil, J; Clackson, T; O'Hagan, R

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020; 8 (): A351

科室
- - 订阅+
  - 更多科室
工具
服务